Cancer Adoptive Cellular Therapy Network (Can-ACT) for Adult Cancers (UG3/UH3 Clinical Trial Required)

Funding Agency:
National Institutes of Health

Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) intends to accelerate development, innovation and establishment of adoptive cellular therapy clinical trials for treatment of adult patients (18 years or older) with solid tumors. Specifically, UG3 phase of the awards will support preclinical, translational and IND-enabling studies that lay groundwork for UH3 early stage clinical trials testing adoptive immune cell therapies in adult patients with solid tumors. This FOA is published in parallel with RFA-CA-22-029 and RFA-CA-22-030 with an aim to develop treatment for pediatric patients with solid tumors and to establish a coordinating center respectively. The awards funded through these three FOAs will collectively comprise the Cancer Adoptive Cellular Therapy (Can-ACT) Network.


  • Letter of Intent Due Date(s): 30 days prior to application due date

  • Application Due Date: October 28, 2022; June 30, 2023

RFA-CA-22-028 Expiration Date July 01, 2023

Agency Website

Amount Description

Application budgets may not exceed $900,000/year in direct costs for UG3 phase and $1,500,000/year in direct costs for UH3 phase (excluding sub-award F&A costs) and must reflect the actual needs of the proposed project.

The scope of the proposed project should determine the project period. The maximum project period is two years for UG3 phase and three years for UH3 phase.

Funding Type





Medical - Basic Science
Medical - Clinical Science

External Deadline

June 30, 2023